Frits Stulp leads consulting department of Iperion

27 July 2015 Consultancy.uk

Iperion, a boutique professional services firm in the Netherlands, has named Frits Stulp Managing Director of its consulting business. The experienced advisor joins from Mesa Arch Consulting, his own consultancy, and previously worked for advisory and tech giant Accenture.

Estbalished in 2005, Iperion is an advisory and implementation firm specialised in the Life Sciences industry. The firm provides quality management systems, GxP cloud computing and consultancy services to among others pharma-biotech companies, medical devices and health care players.

Per the 1st of March Iperion has strengthened its leadership with Frits Stulp. The consultant holds a MSc degree in pharmacochemistry and has in recent years built a strong background in the pharmaceutical industry. He started his career with Yamanouchi, and later served Astellas, a Japanese-origin Pharma giant with global revenues of over $11 billion, where he headed the company’s SAP project management portfolio in Europe. In 2007 Stulp joined Accenture, focusing on clients in the Pharma, Life Sciences and Healthcare sectors.

Frits Stulp - Iperion

Roughly four years later Stulp decided to launch his own business, titled ‘Mesa Arch Consulting’, supporting clients with advisory and project management related activities. As a contractor he led two large implementation programmes at Astellas Pharma. In his new role, Managing Director Consultancy for Iperion, Stulp will be responsible for further development of the Consultancy business unit, including growing the client and service portfolio, as well as boost the firm’s reputation in the marketplace.

“With his extensive experience in program- and project management, regulatory compliance consultancy and information management, Frits is the right person to manage the growing demand for consultancy and support services (system agnostic) in the area of regulatory compliance and IT for pharmaceutical, bio-tech and medical devices companies”, states Iperion in a press release.

News

More news on